Table 2.
Univariable and multivariable Cox regression analysis in each data set.
| Variables | Univariable model | Multivariable model | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI of HR | P value | HR | 95% CI of HR | P value | |
| GEO training set (N = 90) | ||||||
| Gender | 2.089 | 0.147 to 3.805 | 0.162 | 0.753 | 0.280 to 2.028 | 0.575 |
| Age | 1.824 | 1.058 to 3.145 | 0.031 | 1.305 | 0.721 to 2.362 | 0.379 |
| Tobacco use | 1.884 | 1.088 to 3.263 | 0.024 | 1.439 | 0.572 to 3.621 | 0.439 |
| Pathology grade | 1.059 | 0.712 to 1.577 | 0.777 | 1.093 | 0.690 to 1.732 | 0.705 |
| TNM stage | 2.814 | 1.721 to 4.602 | 0.003 | 1.365 | 0.815 to 2.287 | 0.237 |
| LncRNA signature | 2.012 | 1.668 to 2.428 | <0.001 | 1.892 | 1.550 to 2.309 | 0.001 |
| GEO validation set (N = 89) | ||||||
| Gender | 0.703 | 0.317 to 1.560 | 0.386 | 0.399 | 0.154 to 1.032 | 0.058 |
| Age | 1.628 | 0.941 to 2.816 | 0.081 | 2.426 | 0.302 to 4.519 | 0.205 |
| Tobacco use | 1.268 | 0.735 to 2.190 | 0.394 | 1.499 | 0.799 to 2.812 | 0.208 |
| Pathology grade | 0.536 | 0.357 to 0.805 | 0.003 | 0.663 | 0.429 to 1.026 | 0.065 |
| TNM stage | 2.429 | 1.420 to 4.155 | 0.001 | 2.205 | 1.257 to 3.868 | 0.006 |
| LncRNA signature | 2.112 | 1.692 to 2.636 | <0.001 | 2.052 | 1.623 to 2.595 | 0.001 |
| TCGA test set (N = 81) | ||||||
| Gender | 0.027 | 0.000 to 3.411 | 0.144 | 0.001 | 0.000 to 4.401 | 0.977 |
| Age | 1.313 | 0.471 to 3.660 | 0.603 | 1.737 | 0.454 to 6.638 | 0.420 |
| Tobacco use | 0.312 | 0.071 to 1.380 | 0.125 | 0.675 | 0.075 to 6.101 | 0.727 |
| Pathology grade | 1.158 | 0.527 to 2.545 | 0.716 | 0.510 | 0.168 to 1.546 | 0.234 |
| TNM stage | 1.820 | 0.963 to 3.438 | 0.065 | 0.730 | 0.276 to 1.928 | 0.525 |
| LncRNA signature | 2.193 | 1.369 to 3.514 | 0.001 | 2.613 | 1.230 to 5.550 | 0.012 |
In Cox regression analysis, Tumor grade, TNM and LncRNA signature were evaluated as continuous variables. Gender and Tobacco use were evaluated as category variable.